Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Lyra Therapeutics Inc.

    NASDAQ: LYRA · Real-Time Price · USD
    13.61
    1.31 (10.65%)
    At close: Jun 26, 2025, 3:59 PM
    13.40
    -1.54%
    After-hours: Jun 26, 2025, 07:59 PM EDT

    Lyra Therapeutics Statistics

    Share Statistics

    Lyra Therapeutics has 1.33M shares outstanding. The number of shares has increased by -0.59% in one year.

    Shares Outstanding

    n/a
    		 1.33M

    Shares Change (YoY)

    n/a
    		 -0.59%

    Shares Change (QoQ)

    n/a
    		 0.65%

    Owned by Institutions (%)

    n/a
    		 41.29%

    Shares Floating

    n/a
    		 1.33M

    Failed to Deliver (FTD) Shares

    n/a
    		 305

    FTD / Avg. Volume

    n/a
    		 0.04%

    Short Selling Information

    The latest short interest is 82.52K, so 6.23% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 82.52K

    Short % of Shares Out

    n/a
    		 6.23%

    Short % of Float

    n/a
    		 7.79%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -0.14 and the forward PE ratio is -0.66. Lyra Therapeutics's PEG ratio is -0.01.

    PE Ratio

    n/a
    		 -0.14

    Forward PE

    n/a
    		 -0.66

    PS Ratio

    n/a
    		 8.76

    Forward PS

    n/a
    		 0.2

    PB Ratio

    n/a
    		 1.16

    P/FCF Ratio

    n/a
    		 -0.19

    PEG Ratio

    n/a
    		 -0.01
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Lyra Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 3.41, with a Debt / Equity ratio of 2.97.

    Current Ratio

    n/a
    		 3.41

    Quick Ratio

    n/a
    		 3.41

    Debt / Equity

    n/a
    		 2.97

    Debt / EBITDA

    n/a
    		 -0.57

    Debt / FCF

    n/a
    		 -0.48

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $51,133.33

    Profits Per Employee

    n/a
    		 $-3,114,500

    Employee Count

    n/a
    		 30

    Asset Turnover

    n/a
    		 0.02

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 39K

    Effective Tax Rate

    n/a
    		 -0.04%

    Stock Price Statistics

    The stock price has increased by -7.57% in the last 52 weeks. The beta is 0.01, so Lyra Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.01

    52-Week Price Change

    n/a
    		 -7.57%

    50-Day Moving Average

    n/a
    		 8.61

    200-Day Moving Average

    n/a
    		 9.87

    Relative Strength Index (RSI)

    n/a
    		 51.53

    Average Volume (20 Days)

    n/a
    		 678,055

    Income Statement

    In the last 12 months, Lyra Therapeutics had revenue of 1.53M and earned -93.44M in profits. Earnings per share was -71.5.

    Revenue

    n/a
    		 1.53M

    Gross Profit

    n/a
    		 1.06M

    Operating Income

    n/a
    		 -96.35M

    Net Income

    n/a
    		 -93.44M

    EBITDA

    n/a
    		 -60.26M

    EBIT

    n/a
    		 -60.73M

    Earnings Per Share (EPS)

    n/a
    		 -71.5
    Full Income Statement

    Balance Sheet

    The company has 40.58M in cash and 34.38M in debt, giving a net cash position of 6.2M.

    Cash & Cash Equivalents

    n/a
    		 40.58M

    Total Debt

    n/a
    		 34.38M

    Net Cash

    n/a
    		 6.2M

    Retained Earnings

    n/a
    		 -404.79M

    Total Assets

    n/a
    		 56.32M

    Working Capital

    n/a
    		 22.43M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -70.01M and capital expenditures -2.34M, giving a free cash flow of -72.35M.

    Operating Cash Flow

    n/a
    		 -70.01M

    Capital Expenditures

    n/a
    		 -2.34M

    Free Cash Flow

    n/a
    		 -72.35M

    FCF Per Share

    n/a
    		 -55.56
    Full Cash Flow Statement

    Margins

    Gross margin is 69.3%, with operating and profit margins of -6280.83% and -6090.94%.

    Gross Margin

    n/a
    		 69.3%

    Operating Margin

    n/a
    		 -6280.83%

    Pretax Margin

    n/a
    		 -6088.4%

    Profit Margin

    n/a
    		 -6090.94%

    EBITDA Margin

    n/a
    		 -3928.42%

    EBIT Margin

    n/a
    		 -6280.83%

    FCF Margin

    n/a
    		 -4716.36%

    Dividends & Yields

    LYRA does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for LYRA is $16, which is 29.7% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $16

    Price Target Difference

    n/a
    		 29.7%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 2
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on May 28, 2025. It was a backward split with a ratio of 1:50.

    Last Split Date

    n/a
    		 May 28, 2025

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:50

    Scores

    Altman Z-Score

    n/a
    		 -12.1

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist